ClinicalTrials.Veeva

Menu
M

M3 Wake Research | Tucson Neuroscience Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

ABP-671
Glucose
Azeliragon
Zavegepant
Rimegepant
JNJ-40411813
Pimavanserin
BMS-986446
BOTOX
Levetiracetam

Parent organization

This site is a part of M3 Wake Research

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 22 total trials

A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Enrolling
Alzheimer's Disease (AD)
Drug: Placebo
Drug: ABBV-916

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participant...

Invitation-only
Gout
Drug: ABP-671
Drug: Allopurinol

This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent seve...

Active, not recruiting
COVID-19
Biological: NVX-CoV2601 (5μg)
Biological: NVX-CoV2601 (35μg)

This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare th...

Enrolling
Gout
Drug: ABP-671
Other: Placebo

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting
Episodic Migraine
Drug: Placebo
Drug: BOTOX

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Trial sponsors

Pfizer logo
AbbVie logo
A
Acadia Pharmaceuticals logo
A
Bavarian Nordic logo
B
Bristol-Myers Squibb (BMS) logo
CENTOGENE logo
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems